Tau RNAi Oligomeric Duplexes for Selective Tau Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective treatments for neurodegenerative diseases associated with tau protein, such as Alzheimer's disease and frontotemporal dementia, due to the unclear role of tau isoform changes and post-translational modifications in these conditions.
Innovation Solution
The use of RNAi agents, specifically oligomeric duplexes, to reduce tau RNA and protein levels in cells, thereby targeting the underlying causes of these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNAi agents are used to reduce tau protein levels, then therapeutic effect is improved, but potential off-target effects and toxicity increase
Solution Approach 1:
The patent modifies the chemical parameters of the RNAi agent by incorporating 2'-O-methoxyethyl (MOE) modifications at specific positions (n1, n2, n3) of the oligonucleotide sequence. These parameter changes enhance binding affinity and specificity to the target tau mRNA while reducing off-target effects and immunogenicity, thereby improving the therapeutic index
Solution Approach 2:
The patent uses a designed oligonucleotide sequence that is complementary to a specific region of tau mRNA (nucleotides 40-60 of SEQ ID NO: 1). This precise copying approach ensures selective binding and degradation of tau mRNA without affecting other transcripts, reducing off-target effects while maintaining therapeutic efficacy
2Reliability
If tau protein levels are reduced to treat neurodegenerative diseases, then disease symptoms are ameliorated, but understanding of normal tau function may be compromised
Solution Approach 1:
The patent applies local quality by selectively reducing tau protein levels only in pathological contexts where tau aggregates form (neurofibrillary tangles in Alzheimer's disease, tau inclusions in other tauopathies). The RNAi agent targets specific aberrant tau isoforms or phosphorylated forms, preserving normal tau function in healthy neurons while eliminating pathological tau, thus treating disease without compromising understanding of normal physiology
3Measurement precision
If specific oligonucleotide sequences are designed to target tau mRNA, then specificity is improved, but complexity of design and synthesis increases
Solution Approach 1:
The patent segments the tau mRNA target into specific regions and selects a 21-nucleotide sequence (nucleotides 40-60 of SEQ ID NO: 1) that provides optimal specificity. The oligonucleotide is further segmented into functional regions: a 2'-O-methoxyethyl modified region for enhanced stability and binding, and unmodified regions for RNAi activity. This segmentation approach achieves high specificity while managing synthesis complexity through modular design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces tau protein levels and ameliorates symptoms such as loss of memory and motor function, and decreases the number and volume of neurofibrillary inclusions, providing a potential therapeutic approach for tauopathies and related disorders.
Implementation Method 1
RNAi agents, methods, and pharmaceutical compositions for reducing the amount or activity of tau RNA in a cell or animal
Data Source
AI summary
Provided are RNAi agents, methods, and pharmaceutical compositions for reducing the amount or activity of tau RNA in a cell or animal, and in certain instances reducing the amount of tau protein in a cell or animal. Such RNAi agents, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease, including a tauopathy, Alzheimer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, or Dravet's Syndrome.